Previous Page  2 / 6 Next Page
Show Menu
Previous Page 2 / 6 Next Page
Page Background

Volume 4, Issue 5(Suppl)

J Infect Dis Ther

ISSN: 2332-0877 JIDT, an open access journal

Euro Infectious Diseases 2016

September 05-06, 2016

Page 8





Infectious Diseases

September 05-06, 2016 Frankfurt, Germany



Euro-Global Conference on

New technologies for innovative needle-free vaccines


raditional vaccines consist of attenuated or inactivated pathogens, whereas subunit vaccines are based on purified antigens.

Although it would be preferable to exploit noninvasive administration strategies, most vaccines still made use of needles.

In this regard, mucosal vaccines and nanoparticle (NP)-based formulations delivered by transfollicular (TF) route are gaining

interest. However, poor immunogenicity and transport across barriers limit these approaches. Adjuvantation might overcome

these constraints, but only few adjuvants are available for human use and none is active by mucosal route. Our adjuvant

development program led to the discovery of well-defined synthetic immune modulators, which are active when administered

bymucosal route and improve the efficacy of NP-based formulations. Among them, cyclic-di-nucleotides (CDNs) exhibit strong

immune modulatory effects on antigen presenting cells by activation of the type-I IFN and TNF pathways. Co-administration

of CDNs with purified antigens induces strong humoral and cellular responses, which were characterized by a balanced Th1/

Th2 profile and induction of cytotoxic cells. Influenza vaccines adjuvanted with CDNs confer protection against virus challenge

in different preclinical models, including aged mice. Co-administration or formulation with antigen loaded NPs also allowed

triggering antigen specific humoral and cytotoxic responses after TF vaccination, even with a completely intact skin barrier.

This new generation of synthetic adjuvants with well defined molecular targets represents a powerful tool for the rational

design of novel vaccines and immune therapies.


Carlos Alberto Guzman has graduated in Medicine and become board certified in Medical Bacteriology in Argentina. Later, he was graduated as a Doctor of

Medicine and Surgery and obtained his Doctorate in Microbiological Sciences, University Genoa, Italy. In 1994, he became Head of the Vaccine Group at German

Research Centre for Biotechnology, Germany. In 2005, he was appointed as the Head of the Department of Vaccinology and Applied Microbiology (HZI), becoming

later APL-Professor at the Medical School and Member of the Centre for Individualized Infection Medicine, Hannover. His work was instrumental for developing new

adjuvants and antigen delivery systems, leading to more than 200 publications.

[email protected]

Carlos Alberto Guzman

Helmholtz Centre for Infection Research, Germany

Carlos Alberto Guzman, J Infect Dis Ther 2016, 4:5(Suppl)